Filament Health Corp. FLHLF announced that the U. S. Patent and Trademark Office (USPTO) issued a patent that will allow the company to extract and standardize natural psilocybin and associated psychedelic compounds.
Benjamin Lightburn, CEO of the company, commented: “The issuance of Filament's first US patent is a testament to the strength of our drug development platform.”
The company also holds the first-ever Canadian patent for extracting and standardizing natural psilocybin for a public company, as announced in August 2021. The process is undertaken by Filament’s subsidiary, Psilo Scientific.
”Shepherding an application to issuance is different in every country, therefore having our IP validated by more than one government is evidence of our team's talent for innovation by truly diverse criteria,” added Taran Grey, director of intellectual property.
Photo: Courtesy of Marco Allegretti on Unsplash
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Missed the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF